The Community Advisory Panel (CAP) is a new mechanism aimed to provide advice to the Medicines Patent Pool (MPP) and its Expert Advisory Group (EAG). Accordingly, community representatives and other individuals with lived experience across a variety of disease areas within MPP’s broad mandate (i.e., HIV, viral hepatitis, TB, malaria, cancer, diabetes, COVID-19, and reproductive, maternal, newborn and child health) are invited to apply.

Geneva, 21 September 2021 – The Medicines Patent Pool (MPP) today announced that it has signed a licence agreement with Tandem Nano Ltd (TNL), the University of Liverpool (UoL) start-up focused on the development of its proprietary long-acting nanosystems platform technology. The non-exclusive, worldwide licence covers the patents and expertise of promising long-acting injectable technologies (LAIs) that could be applied in three disease areas with a high prevalence in low- and middle-income countries (LMICs): malaria, tuberculosis (TB), and hepatitis C (HCV). The candidate LAIs, currently developed by the Centre of Excellence for Long-acting Therapeutics (CELT) based at UoL, could provide optimal doses of medicines for malaria chemoprophylaxis, TB prevention, and HCV cure. The research teams are designing medicines to be delivered through a single injection to achieve the desired effect on the pathogens over prolonged periods, suppressing the need for daily oral pills, among many other advantages at the individual and the community levels.

The Medicines Patent Pool (MPP) and the Bill & Melinda Gates Medical Research Institute signed an agreement to advance the development of investigational sutezolid-containing TB drug regimens, especially for low- and middle-income countries, where most people with TB live. The drug candidate sutezolid, in combination with other drugs, could potentially be used as an all-oral, shortened regimen for all forms of TB, including multidrug-resistant TB.

Strategy and related feasibility study call for the expansion of the MPP’s mandate to patented medicines on the World Health Organization’s Model List of Essential Medicines

Non-remunerated position.

Geneva, 31 October 2017 — The Medicines Patent Pool (MPP) and TB Alliance signed a Memorandum of Understanding (MoU) to facilitate third-party development of sutezolid-containing tuberculosis regimens. The MoU follows the sublicensing agreement signed by both organisations in March 2017 granting TB Alliance the rights to develop sutezolid, a promising antibiotic drug candidate, in combination with other TB drugs for drug-susceptible and drug-resistant TB patients.

Geneva, 11 October 2017 — The Medicines Patent Pool (MPP) announced that it has signed a Memorandum of Understanding (MoU) with Otsuka to accelerate the development and manufacturing of, and access to, paediatric formulations containing delamanid for multidrug-resistant tuberculosis (MDR-TB).

The Medicines Patent Pool (MPP) released a short film, in which MPP’s stakeholders from industry, government, civil society and patient groups discuss the foundation’s innovative business model, achievements and future plans to increase access to HIV, hepatitis C and TB treatment within the context of the UN Sustainable Development Goals.

Agreement announced on World Tuberculosis Day revitalizes efforts to develop sutezolid as effective response to infectious disease killer.

In the context of its mandate expansion into tuberculosis, the Medicines Patent Pool (MPP) was asked by its funder, UNITAID, to conduct a study to examine how MPP licences could contribute to addressing some of the stewardship challenges for new drugs for tuberculosis, specifically for multidrug-resistant TB. The report seeks to inform the Foundation’s approach to negotiating licences and sub-licences for the manufacturing of TB compounds. It acknowledges the twin public health goals of ensuring broad availability of new therapies while promoting their proper use to counter further resistance.